Business · 13/02/2026Updated: 10/16/2026 · 1 min read
FDA Determines Regulatory Review Period for AMTAGVI Patent Extension
Summary
The FDA has determined the regulatory review period for AMTAGVI, a human biological product, due to patent extension applications submitted to the USPTO.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →